Clinical Trial Update: Effect of AQW051 in Patients With Memory Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial of AQW051 in memory impairment (Mild Alzheimer's disease and amnestic mild cognitive impairment) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• AQW051

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Mild Alzheimer's Disease, Amnestic Mild Cognitive Impairment | Phase 2 | Status: TERMINATED